Lantern Pharma (LTRN) announced that withZeta.ai, a comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development, is now commercially live and actively onboarding subscribers. Subscriptions are available immediately at withzeta.ai, spanning introductory, academic, and commercial tiers, and represent a new, non-dilutive revenue stream for Lantern Pharma shareholders. The platform’s commercial debut will be showcased through two landmark events: a private investor briefing at Nasdaq MarketSite in New York City on April 16, 2026, and public demonstrations at the American Association for Cancer Research Annual Meeting 2026 in San Diego at Booth 5054 during April 17-22.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN:
- Lantern Pharma Showcases withZeta.ai Platform for Rare Cancers
- Lantern Pharma to host live demonstration of withZeta.ai
- Why Is Vanguard Total Stock Market ETF (VTI) Rising Today, 3/31/26?
- Lantern Pharma Reports 2025 Results and Pipeline Progress
- Closing Bell Movers: Phreesia down over 20% after guidance cut